The impact of neuromyelitis optica spectrum disorder on pregnancy outcome

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome

Bibliographic Details
Main Authors:	Nour, M, Coutinho, E, Nakashima, I, Sousa, F, Revis, J, Santos, E, George, J, Kitley, J, Misu, T, Woodhall, M, Silva, A, Vincent, A, Waters, P, Palace, J, Fujihara, K, Leite, M
Format:	Conference item
Published:	2014

Similar Items

PREGNANCY OUTCOME IN AQUAPORIN-4 POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER: A MULTI-CENTER RETROSPECTIVE COHORT STUDY
by: Nour, M, et al.
Published: (2014)

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
by: Nour, M, et al.
Published: (2015)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
by: Kim, W, et al.
Published: (2012)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
by: Kitley, J, et al.
Published: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
by: Kitley, J, et al.
Published: (2013)

Pain in neuromyelitis optica spectrum disease: a cross-sectional study in an English cohort
by: Leonard, H, et al.
Published: (2012)

Alternative antigen targets in aquaporin-4 antibodynegative neuromyelitis optica spectrum disorders
by: Kitley, J, et al.
Published: (2013)

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
by: Kitley, J, et al.
Published: (2012)

Aquaporin-4 Antibody Isoform Binding Specificity Does Not Explain Clinical Variations in Neuromyelitis Optica
by: Kitley, J, et al.
Published: (2013)

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
by: Kitley, J, et al.
Published: (2014)

Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies A Comparative Study
by: Kitley, J, et al.
Published: (2014)

Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply.
by: Kitley, J, et al.
Published: (2014)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
by: Kitley, J, et al.
Published: (2012)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan
by: Kitley, J, et al.
Published: (2012)

Use of mitoxantrone in neuromyelitis optica.
by: Kitley, J, et al.
Published: (2011)

Myelin-oligodendrocyte glycoprotein antibody-mediated acute inflammatory demyelinating disease mimicking neuromyelitis optica
by: Kitley, J, et al.
Published: (2011)

MYELIN-OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY AS A CAUSE OF ACUTE DISSEMINATED ENCEPHALOMYELITIS WITH A NEUROMYELITIS OPTICA-LIKE PHENOTYPE IN ADULTS
by: Kitley, J, et al.
Published: (2012)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
by: Waters, P, et al.
Published: (2016)

Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders
by: Sato, D, et al.
Published: (2014)

Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features.
by: Absoud, M, et al.
Published: (2014)

NEUROMYELITIS OPTICA SPECTRUM DISORDER AND CMV RETINITIS: A CASE REPORT
by: George, J, et al.
Published: (2012)

The evolving clinical spectrum of neuromyelitis optica
by: Viegas, S, et al.
Published: (2008)

Spinal cord MRI features in neuromyelitis optica (NMO): characteristics and relationship with severity and recovery in longitudinally extensive transverse myelitis (LETM) attacks
by: Murchison, A, et al.
Published: (2013)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
by: Collongues, N, et al.
Published: (2013)

Risk factors for immunosuppression-associated infections in aquaporin-4 antibody mediated neuromyelitis optica spectrum disorders
by: Cheng, F, et al.
Published: (2014)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
by: Waters, P, et al.
Published: (2015)

NEUROMYELITIS OPTICA SPECTRUM AND RELATIONSHIP WITH AQUAPORIN-4 ANTIBODY DISEASE: THE OXFORD COHORT
by: Leite, M, et al.
Published: (2009)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
by: Kitley, J, et al.
Published: (2014)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.
by: Kitley, J, et al.
Published: (2014)

METHOTREXATE MAY BE AN ALTERNATIVE TO AZATHIOPRINE IN NEUROMYELITIS OPTICA WITH AQUAPORIN-4 ANTIBODIES
by: Kitley, J, et al.
Published: (2012)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
by: Fujihara, K, et al.
Published: (2014)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
by: Pittock, S, et al.
Published: (2019)

NEUROMYELITIS OPTICA IN SOUTH WALES AND THE SOUTH WEST OF ENGLAND
by: Luppe, S, et al.
Published: (2012)

Differential diagnosis of neuromyelitis optica spectrum disorders
by: Sung-Min Kim, et al.
Published: (2017-07-01)

LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS: A VARIETY OF CAUSES SEEN WITHIN THE NATIONAL NEUROMYELITIS OPTICA SERVICE
by: Kitley, J, et al.
Published: (2012)

CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder
by: Chihiro Namatame, et al.
Published: (2021-01-01)

Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
by: Tackley, G, et al.
Published: (2016)

Seasonal pattern of variation in neuromyelitis optica relapses
by: Elsone, L, et al.
Published: (2012)

DIFFERENCES IN OUTCOMES IN NEUROMYELITIS OPTICA BETWEEN A JAPANESE COHORT AND A PREDOMINANTLY CAUCASIAN COHORT FROM THE UK
by: Kitley, J, et al.
Published: (2012)

Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.
by: Viegas, S, et al.
Published: (2009)